{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"800"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"description":"The RP2D and schedule were defined by the Cohort Review Committee at the end of the study and took all clinically relevant toxicity, PK and PDn data into account. The RP2D was to be a dose equal to or less than the MTD for the selected schedule.","groups":[{"description":"The Safety Evaluable Population includes all enrolled subjects who receive at least 1 dose of SRA737.","id":"OG000","title":"Safety Evaluable Population"}],"paramType":"NUMBER","populationDescription":"All 107 subjects treated in the study were included in the review of toxicity, PK and PDn, data in order to determine the RP2D. All clinically relevant toxicity, PK and PDn data up to 30 days after last dose of SRA737 were taken into account.","reportingStatus":"POSTED","timeFrame":"Up to 30 days after last dose of SRA737","title":"Recommended Phase 2 Dose of SRA737","type":"PRIMARY","unitOfMeasure":"mg QD"}